Samsung BioLogics Archives | Page 2 of 6

Home / Posts tagged Samsung BioLogics (Page 2)

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market LOWELL, Mass., Jan. 04, 2024 (Korea Bizwire) – Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and [...]

Samsung Biologics Inks US$390.9 mln Manufacturing Deal with Novartis

SEOUL, July 10 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has signed a US$390.9 million deal with Novartis Pharma AG to manufacture the Switzerland-based pharmaceutical firm’s products. It is the final contract for an investment letter of intent announced in June last year, in which [...]

Samsung Biologics Seals US$1.08 bln Manufacturing Deals with Pfizer

SEOUL, July 4 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has sealed a combined US$1.08 billion partnership contracts with U.S. pharmaceutical giant Pfizer so far this year. The Korean company said it signed a new contract with Pfizer, a follow-up to the bilateral deal set [...]

Samsung Biologics Inks US$411.3 mln Manufacturing Deal with Pfizer

SEOUL, June 8 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Thursday it has signed a US$411.3 million contract with Pfizer to manufacture the U.S. pharmaceutical firm’s products. Under the deal with Pfizer, Samsung Biologics will manufacture Pfizer’s multi-product biosimilar portfolio, including oncology, inflammation and immunotherapy, at its [...]

Samsung Biologics to Start Operation of New Facilities in April 2025

SEOUL, June 6 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Tuesday it will move up the operation of its new biomedicine production facility by five months in a way to deal with rising demand. The company has invested 1.98 trillion won (US$1.51 billion) to build Plant 5 [...]

Samsung Biologics 2022 Net Income More than Doubles

SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday its 2022 net income more than doubled on strong overseas sales of its biomedicine products after its takeover of Samsung Bioepis Co. Its net income reached 798.1 billion won (US$648.1 million) in 2022, up 102.8 percent [...]

Samsung Biologics to Invest 7.5 tln Won to Build New Production Facilities

SEOUL, Jan. 12 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Thursday it will invest 7.5 trillion won (US$6 billion) to build a new biomedicine production complex west of Seoul. Samsung Biologics CEO John Rim said in the J.P. Morgan Healthcare Conference in San Francisco that the new [...]

Samsung’s De Facto Leader Lee Attends Opening Ceremony of Samsung Biologics’ Fourth Plant

SEOUL, Oct. 11 (Korea Bizwire) — Samsung Group’s de facto leader Lee Jae-yong on Tuesday attended the opening ceremony of the fourth plant of Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, in a sign of the group’s dedication to nurture biopharmaceuticals as one of its next growth drivers. The plant, which [...]

Samsung Biologics Tentatively Agrees to Work with AstraZeneca on Contract Manufacturing

SEOUL, Aug. 12 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday it has tentatively agreed to work with multinational pharmaceutical company AstraZeneca on biopharmaceutical contract manufacturing. The company said in a regulatory filing that it signed a letter of intent on the cooperation in a deal valued [...]

Samsung Biologics Signs 426 bln-won Land Purchase Deal to Build 2nd Campus

SEOUL, July 18 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, on Monday signed a land purchase contract worth 426 billion won (US$323 million) to build a second campus inside a free economic zone west of Seoul. The deal signed between Incheon metropolitan city and Samsung Biologics would allow [...]